EP0871741A1 - Nouveaux vecteurs d'expression destines a la production de proteines exogenes sous formes solubles - Google Patents

Nouveaux vecteurs d'expression destines a la production de proteines exogenes sous formes solubles

Info

Publication number
EP0871741A1
EP0871741A1 EP97943210A EP97943210A EP0871741A1 EP 0871741 A1 EP0871741 A1 EP 0871741A1 EP 97943210 A EP97943210 A EP 97943210A EP 97943210 A EP97943210 A EP 97943210A EP 0871741 A1 EP0871741 A1 EP 0871741A1
Authority
EP
European Patent Office
Prior art keywords
expression vector
protein
gene
lys
coli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97943210A
Other languages
German (de)
English (en)
Inventor
Seong Il Choi
Baik Lin Seong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanil Synthetic Fiber Co Ltd
Original Assignee
Hanil Synthetic Fiber Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanil Synthetic Fiber Co Ltd filed Critical Hanil Synthetic Fiber Co Ltd
Publication of EP0871741A1 publication Critical patent/EP0871741A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Definitions

  • the present invention relates to novel expression vectors which can
  • the present invention relates to the expression
  • E. coli has been exploited as a popular host cell to produce foreign proteins
  • the refolding process for preparing a active protein can be any suitable refolding process.
  • proteins having high molecular weight such as
  • chaperone genes such as groES, groEL, dnaK and the like to obtain
  • translation initiation signal of the fusion partner protein can be
  • Lac Z or Trp E protein have been utilized as a fusion partner
  • transformant should be cultured at low temperature such as 15°C in order to produce
  • Lysyl-tRNA synthetase (hereinafter it refers to "Lys RS") and its gene have been investigated as described below, which is preferable for the
  • lys S gene is expressed constitutively in normal condition
  • Lys U protein is
  • NMR nuclear magnetic resonance
  • Lys S lys S gene
  • Lys U protein and Lys S protein share a high degree of identity in the amino acid sequences, the N-terminal structures of the two
  • N-terminal domain of lysyl-tRNA synthetase has
  • H4 ⁇ -helix
  • Lys S protein has
  • Lys S protein is
  • Lys S protein as a fusion partner makes heterodimer with Lys S protein of E. coli.
  • Lys S protein is not appropriate as a fusion partner protein
  • Lys RS protein has a secondary structure which facilitates protein folding
  • lysyl-tRNA synthetase can be utilized as a fusion partner protein to
  • the object of the present invention is to provide expression vectors
  • aminoacyl-tRNA synthetase gene can be obtained from all kinds of cells.
  • the expression vectors of the present invention are composed of
  • linker peptide sequence linker peptide sequence, tag sequence, protease recognition site, restriction
  • the object of the present invention is to provide the E.
  • the lysyl-tRNA synthetase gene can be selected among lys S gene
  • the present invention provides the expression vector
  • the object of the present invention is to provide the
  • the present invention provides the expression vectors containing
  • the present invention provides the expression vector
  • the expression vectors contain the N-terminal domain gene of lysyl-tRNA
  • the present invention provides the E. coli expression
  • the object of the present invention is to provide a process for
  • the present invention provides the expression vector
  • GMcsf human granulocyte and macrophage
  • colony stimulating factor gene into the expression vector pGE-lysN.
  • GMcsf protein as a fusion protein.
  • E. coli preferably, E. coli
  • HMS 174 strain can be used as a host cell.
  • the present invention provides the expression vector plysN-Gcsf by inserting Gcsf (human granulocyte colony stimulating
  • the present invention provides the expression vector
  • TIMP2 human tissue inhibitor of TIMP2
  • metalloprotease 2 gene into the expression vector.
  • TIMP2 protein is prepared.
  • Fig. 1 depicts the secondary structure of lysyl-tRNA synthetase
  • Stick is helix structure and arrow is ⁇ -sheet structure.
  • Fig. 2 depicts a strategy for constructing the expression vector
  • Fig. 3 depicts the expression of Lys S protein by performing SDS-
  • lane 1 standard protein marker
  • lane 2 total proteins of E. coli induced for the protein expression ;
  • Fig. 4 depicts a strategy for constructing the expression vector
  • Fig. 5 depicts a strategy for constructing the E. coli expression
  • vector pLysN-GMcsf which expresses GMcsf protein by using the
  • Fig. 6 depicts the expression of GMcsf protein by performing
  • Fig. 7 depicts the expression of GMcsf protein for comparison by
  • Fig. 8 depicts a strategy for constructing the E. coli expression
  • vector pLysN-Gcsf which expresses Gcsf protein by using the expression
  • Fig. 9 depicts the expression of Gcsf protein by performing SDS-
  • Fig. 11 depicts the expression of TIMP2 protein by performing SDS-
  • lane 3 total proteins of is. co///pGE-lysN transformant induced for
  • the present invention provides expression vectors which produce
  • aminoacyl-tRNA synthetase characteristics of aminoacyl-tRNA synthetase. All kinds of aminoacyl-tRNA synthetase.
  • tRNA synthetase genes can be used to prepare expression vectors of the
  • the present invention provides expression vectors which use lysyl-
  • Lys RS protein gene can be selected among lys S gene and lys
  • Lys RS protein gene can be obtained by performing polymerase
  • PCR chain reaction
  • plasmid vector such as pGEMEX M -l (Promega) so as to
  • E. coli strains proper for the expression have been transformed with
  • Lys RS protein was expressed well, to 80% of total soluble proteins of the host cell.
  • E. coli transformants are cultured at
  • the present invention provides expression vectors which uses the
  • N- terminal domain of Lys RS protein as a fusion partner protein N- terminal domain of Lys RS protein as a fusion partner protein.
  • expression vector of the present invention contains linker peptide sequence
  • vectors can be produced as forms of soluble proteins in the host cells and
  • N-terminal domain gene of Lys RS protein can be
  • the E. coli HMS 174 strain was transformed by the expresseion
  • the expression vector constructed by the above process has the
  • T7 promoter which regulates transcription of the fusion protein.
  • coli strans such as tac promoter, ⁇ pL promoter and the like, is available for
  • Lys RS protein constructed in order to exploit the N-terminal domain of Lys RS protein as a
  • enteropeptidase from digesting fusion protein and affect protein folding.
  • helix 1 structure can be removed from the expression
  • the present invention provides the expression vector removed at the
  • the expression vector of the present invention contains
  • the expression vector also contains the N-
  • invention contains OB fold gene which is involved in folding process of Lys
  • the expression vector contains the N-terminal
  • Lys RS protein which is deleted at the amino acid residues 1 to
  • the expression vector of the present invention can also contain OB
  • Staphylococcal nuclease can be utilized for the construction of the
  • the expression vector of the present invention contains linker
  • This linker peptide is very useful since it is protruded on the
  • the expression vector can also contain
  • the expression vector of the present invention also contains
  • histidine tag of 6 histidine residues after the above linker peptide This
  • histidine tag enables the fusion proteins expressed with the expression
  • histidine tagged fusion protein can be purified easily. Practically, histidine tagged fusion protein can be purified easily. Practically, histidine tagged fusion protein can be purified easily. Practically, histidine tagged fusion protein can be used.
  • Fusion proteins can be inserted into the expression vector. Fusion proteins
  • the expression vector of the present invention contains protease recognition site in order to separate only foreign protein from fusion protein
  • invention contains enteropeptidase recognition site (DDDDK sequence)
  • enteropeptidase digests the C-terminus of the above enteropeptidase
  • thrombin recognition site LVPRGS sequence
  • Xa factor thrombin recognition site
  • the expression vector of the present invention contains restriction
  • lysN of the present invention contains restriction enzyme recognition sites
  • the present invention provides the expression vectors
  • GMcsf human granulocyte colony stimulating factor
  • Gcsf human granulocyte colony stimulating factor
  • TMP 2 human tissue inhibitor of metalloprotease
  • the present invention constructs the expression vector which
  • GMcsf gene was obtained by performing polymerase chain reaction
  • GMcsf protein fused with thioredoxin according to their expression.
  • the present invention constructs the expression vector which produces Gcsf protein as a soluble form.
  • Gcsf gene was
  • the present invention constructs the expression vector
  • TIMP 2 protein as a soluble protein.
  • TIMP 2 TIMP 2
  • the E. coli strains proper for the expression have been transformed
  • Lys N protien namely, Lys
  • fusion protein was expressed as an inclusion
  • Lys N protein of the present invention is
  • PCR polymerase chain reaction
  • PBS phosphate buffered saline
  • each sample was mixed with 7 ⁇ l of 5 X SDS loading buffer, and boiled for
  • the present invention expresses Lys S protein highly at the ratio of 80% of
  • Example 1 as a template (see Sequence Listing).
  • the expression vector containing the N-terminal domain gene of Lys S protein was constructed and named as the expression vector
  • PCR was performed by utilizing
  • primer 4 of SEQ ID. NO: 4 primer 5 of SEQ ID. NO: 5 and the expression
  • present invention was also digested with Kpnl and Hindlll. And the above
  • E. coli was transformed with the expression vector
  • fusion protein was constructed by subcloning GMcsf gene into Kpnl and
  • present invention was cultured at 37°C, fusion proteins were expressed as
  • thioredoxin was less effective than Lys N protein as a
  • LysN-Gcsf fusion protein In order to express human Gcsf (granulocyte colony stimulating
  • Example 1 were ligated after elution by performing the same method of Example 1.
  • fusion protein was expressed by fransfoiming E. coli
  • Lys-Gcsf fusion protein was expressed as a
  • metalloprotease 2 as a soluble protein, which has been expressed as an
  • TIMP2 gene was inserted into the expression
  • vector pGE-lysN of the present invention vector pGE-lysN of the present invention.
  • fusion protein was expressed by transforming E. coli
  • Lys N-TIMP2 fusion protein was expressed as a
  • the expression vectors of the present invention expresses lysyl-
  • the expression vector of the present invention expresses
  • Lys RS protein highly at the ratio of 80% of total soluble proteins
  • Lys N protein is more effective than thioredoxin
  • the expression vectors of the present invention can be any expression vectors of the present invention.
  • the expression vectors of the present invention can be any expression vectors of the present invention.
  • present invention is useful to produce foreign proteins which are difficult or
  • the expression vector of the present invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne de nouveaux vecteurs d'expression qui permettent de produire des protéines exogènes sous des formes solubles en utilisant une synthétase lysyl-ARNt. Cette invention concerne également un procédé de préparation de protéines exogènes faisant appel à ces vecteurs d'expression. Cette invention concerne plus particulièrement des vecteurs d'expression qui permettent d'obtenir des protéines exogènes sous des formes fusionnées et solubles, lequel procédé consiste à utiliser la structure et le diagramme d'expression de synthétase lysyl-ARNt. Cette invention concerne enfin des procédés qui permettent de préparer efficacement des protéines exogènes dans des E. coli, et qui peuvent être utilisés dans l'industrie afin de produire de grandes quantités de protéines actives.
EP97943210A 1996-10-04 1997-10-04 Nouveaux vecteurs d'expression destines a la production de proteines exogenes sous formes solubles Withdrawn EP0871741A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1019960044010A KR100203919B1 (ko) 1996-10-04 1996-10-04 수용성 단백질을 생산하는 새로운 발현 플라스미드
KR4401096 1996-10-04
PCT/KR1997/000186 WO1998014591A1 (fr) 1996-10-04 1997-10-04 Nouveaux vecteurs d'expression destines a la production de proteines exogenes sous formes solubles

Publications (1)

Publication Number Publication Date
EP0871741A1 true EP0871741A1 (fr) 1998-10-21

Family

ID=19476265

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97943210A Withdrawn EP0871741A1 (fr) 1996-10-04 1997-10-04 Nouveaux vecteurs d'expression destines a la production de proteines exogenes sous formes solubles

Country Status (4)

Country Link
EP (1) EP0871741A1 (fr)
KR (1) KR100203919B1 (fr)
AU (1) AU725755B2 (fr)
WO (1) WO1998014591A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1298000A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人Ⅱ类氨酰基－tRN A合成酶9和编码这种多肽的多核苷酸
CN1307106A (zh) * 2000-01-26 2001-08-08 上海博道基因技术有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶75和编码这种多肽的多核苷酸
WO2002010396A1 (fr) * 2000-07-28 2002-02-07 Mogam Biotechnology Research Institute Systeme d'expression genetique pour production en masse d'arn polymerase dependante de l'arn du virus de l'hepatite c, et dosage enzymatique utilisant la proteine de fusion exprimee a partir de ce systeme
KR20020010241A (ko) * 2000-07-28 2002-02-04 허영섭 Ｃ형 간염 바이러스 ｒｎａ-의존성 ｒｎａ 중합효소의대량 발현 기구 및 이로부터 발현된 융합단백질을 이용한효소활성 분석방법
KR100890579B1 (ko) * 2002-08-19 2009-04-27 프로테온 주식회사 Ｒｎａ 결합 단백질의 유전자를 융합파트너로 이용한재조합 단백질의 제조방법
KR100484653B1 (ko) 2004-05-06 2005-04-20 주식회사 대웅 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터
KR101023518B1 (ko) * 2008-12-29 2011-03-21 고려대학교 산학협력단 아스파라긴산 카르바모일트렌스퍼레이즈 촉매 사슬을 융합발현파트너로 이용한 가용성 재조합 단백질의 제조방법
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8986681B2 (en) 2010-04-27 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
EP2563383B1 (fr) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Découverte innovatrice de compositions thérapeutiques, diagnostiques, et d'anticorps associées aux fragments protéiques des valyle arnt synthétases
WO2011150279A2 (fr) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à fragments protéiques de glutaminyl-arnt synthétases
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2566496B1 (fr) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées des fragments protéiques de méthionyl-arnt-synthétases
CN103108655B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与丝氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CA2797277C (fr) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps liees a des fragments proteiques d'arginyle-arnt synthetases
CA2798301C (fr) 2010-05-04 2020-09-15 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, diagnostiques et a base d'anticorps liees a des fragments proteiques de glutamyl-prolyl-arnt-synthetases
CA2798139C (fr) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, diagnostiques et a base d'anticorps liees a des fragments proteiques de complexe multi-arnt synthetase p38
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011261486B2 (en) * 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
EP2593125B1 (fr) 2010-07-12 2017-11-01 aTyr Pharma, Inc. DÉCOUVERTE INNOVANTE DE COMPOSITIONS THÉRAPEUTIQUES, DE DIAGNOSTIC ET D'ANTICORPS SE RAPPORTANT À DES FRAGMENTS PROTÉIQUES DE GLYCYL-ARNt SYNTHÉTASES
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
NZ603811A (en) 2010-07-12 2015-03-27 Atyr Pharma Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2812795C (fr) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Decouverte innovante de fragments de proteine de tryptophanyle arnt synthetases associes a des compositions therapeutiques, diagnostiques et d'anticorps
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
KR101360375B1 (ko) * 2011-08-19 2014-02-10 연세대학교 산학협력단 수용성 ｂｍｐ-2를 생산하는 재조합 대장균 및 이를 이용한 수용성 ｂｍｐ-2의 제조방법
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
CA2858613A1 (fr) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Conjugues aspartyl-arnt synthetase-fc
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
KR101908438B1 (ko) * 2016-02-05 2018-10-16 (주)피앤피바이오팜 Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
KR101816081B1 (ko) * 2016-06-03 2018-01-08 연세대학교 산학협력단 백일해균 유래 LysRS를 포함하는 항원 단백질 및 이를 이용한 백일해 진단 방법
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62278992A (ja) * 1986-05-28 1987-12-03 Unitika Ltd ジアデノシン四リン酸又はその誘導体の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9814591A1 *

Also Published As

Publication number Publication date
WO1998014591A1 (fr) 1998-04-09
AU4473597A (en) 1998-04-24
KR100203919B1 (ko) 1999-06-15
AU725755B2 (en) 2000-10-19
KR19980025768A (ko) 1998-07-15

Similar Documents

Publication Publication Date Title
AU725755B2 (en) Novel expression vectors for production of foreign proteins as soluble forms
US6852512B2 (en) Expression vectors for production of foreign proteins as soluble forms
LaVallie et al. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm
KR860001305B1 (ko) 특이적 절단 링커를 사용하는 융합 단백질의 제조방법
LaVallie et al. [21] Thioredoxin as a fusion partner for production of soluble recombinant proteins in Escherichia coli
Murby et al. Upstream strategies to minimize proteolytic degradation upon recombinant production inEscherichia coli
KR100251054B1 (ko) 합성 리더 펩티드 서열
US5252466A (en) Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them
US6207420B1 (en) Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in Escherichia coli
KR101363299B1 (ko) 염기성 아미노산 ｃ-말단을 갖는 폴리펩티드를 특이적인엔도프로테아제를 사용하여 아미드화시키는 방법
EP1364029B1 (fr) PROTEINE DE FUSION comprenante hirudin et proinsuline or insuline
Pines et al. Expression and secretion of proteins in E. coli
Liew et al. Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites
US5232841A (en) Expression vectors containing a bacillus brevis signal sequence
LaVallie et al. Thioredoxin and related proteins as multifunctional fusion tags for soluble expression in E. coli
Sagiya et al. Direct high-level secretion into the culture medium of tuna growth hormone in biologically active form by Bacillus brevis
US8080387B2 (en) Method for preparing soluble and active recombinant proteins usins PDI as a fusion partner
JP2012525143A (ja) 不溶性の組み換えタンパク質に対して溶解性を付与する新規な融合タグ
KR20140004219A (ko) 대장균에서 이형 단백질 생산을 위한 새로운 발현 및 분비 벡터 시스템
EP0614982A1 (fr) Vecteur récombinant pour la préparation exocellulaire d'anticorps monocaténaires exprimés dans Bacillus Subtilis
AU674741B2 (en) Methods and DNA expression systems for over-expression of proteins in host cells
AU647025B2 (en) Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
David et al. Semisynthesis and application of carboxyfluorescein-labelled biologically active human interleukin-8
WO2001068884A1 (fr) Procede de preparation d'un polypeptide comprenant une liaison disulfure
US20140154742A1 (en) Novel expression and secretion vector systems for heterologous protein production in escherichia coli

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 20010705

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050922